Target intelligence / Profile preview

UDP-N-acetylmuramoyl-L-alanine–D-glutamate ligase (MurD)

Target
MurD
Molecular classification
Enzyme, Ligase, Peptidoglycan biosynthesis enzyme
01

Overview

UDP-N-acetylmuramoyl-L-alanine–D-glutamate ligase (MurD) is an essential cytoplasmic enzyme in bacteria that catalyzes the ATP-dependent addition of D-glutamic acid to UDP-N-acetylmuramoyl-L-alanine, producing UDP-N-acetylmuramoyl-L-alanine–D-glutamate, a critical step in peptidoglycan precursor biosynthesis. MurD, along with MurC, MurE, and MurF, forms a family of peptidoglycan peptide ligases responsible for sequentially adding amino acids to the glycan backbone precursor. These enzymatic steps are vital for maintaining bacterial cell wall integrity and survival. MurD's essential role in bacterial viability and absence in mammals make it an attractive and validated target for new antibacterial agents, although no clinically approved inhibitors exist yet[2][3][7]. The enzyme has been extensively studied in structural and mechanistic terms, facilitating rational drug design efforts.

Other names
MurDD-glutamic acid–adding enzymeUDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase
02

Mechanism of action

Inhibition of MurD prevents the addition of D-glutamic acid to UDP-MurNAc-L-Ala, blocking peptidoglycan synthesis and leading to bacterial cell death[2][3].

03

Biological functions

Cell wall biosynthesisPeptidoglycan precursor assemblyBacterial cell viability
04

Disease associations

Infection (critical for survival of most pathogenic bacteria)
05

Safety considerations

Target specificity: off-target effects on human or commensal flora must be avoided; development of resistance is a general challenge for antibiotics targeting bacterial cell wall biosynthesis
06

Interacting drugs

Experimental MurD inhibitors (e.g., 5-benzylidenerhodanine derivatives)

1 more in the full profile.

07

Biomarkers

None currently established for patient selection or monitoring efficacy

Beyond the preview

Go deeper on UDP-N-acetylmuramoyl-L-alanine–D-glutamate ligase (MurD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UDP-N-acetylmuramoyl-L-alanine–D-glutamate ligase (MurD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call